Last updated: June 24, 2026

Few research peptides have a clinical record as specific as tesamorelin. Across multiple Phase 3 trials, the tesamorelin visceral fat reduction percentage has been measured directly with CT imaging, and the results are remarkably consistent. Researchers searching for hard numbers — not vague promises — keep arriving at the same question: how much visceral adipose tissue does this growth hormone-releasing hormone analog actually reduce, and how quickly?

This guide answers that question first, then explains the science behind it. You will find the measured VAT reduction percentage, the 26-week timeline, the mechanism of action, and how tesamorelin compares with other metabolic research peptides. Because the data comes from registrational human trials, the figures are unusually well documented. Throughout, the focus stays on research context, and every product referenced is intended strictly for laboratory study.

Quick answer

In Phase 3 clinical trials, tesamorelin reduced visceral adipose tissue (VAT) by approximately 15–18% at 26 weeks, measured by CT scan at the L4–L5 vertebral level. The reduction was significant compared with placebo, appeared by week 13, and largely reversed when the peptide was discontinued — indicating that continued administration was required to maintain the effect.

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog — a stabilized 44-amino-acid peptide that signals the pituitary gland to release the body’s own growth hormone in a natural, pulsatile pattern. Unlike direct growth hormone administration, it works one step upstream, which is why it became a subject of intense clinical interest for visceral fat research.

It was first studied for HIV-associated lipodystrophy, a condition marked by excess visceral adipose tissue. That research context is important: the Phase 3 trials were specifically designed to measure VAT change, so the tesamorelin visceral fat reduction percentage is one of the best-documented efficacy figures in the entire peptide literature.

The following findings are drawn from registrational Phase 3 trials and their published analyses. Each one is framed for research interpretation.

1. Roughly 15–18% VAT reduction. The headline result: visceral adipose tissue fell by approximately 15–18% at 26 weeks versus a slight increase under placebo, measured by single-slice CT.
2. Effect appeared by week 13. Interim measurement showed meaningful VAT separation from placebo at the halfway point, indicating a relatively rapid onset.
3. Subcutaneous fat was largely spared. The reduction was selective for visceral fat; subcutaneous adipose tissue changed comparatively little, a key distinction in the research data.
4. Triglycerides improved. Trials reported reductions in triglycerides and improvements in several lipid parameters alongside the VAT change.
5. IGF-1 rose as expected. Because tesamorelin stimulates growth hormone release, insulin-like growth factor 1 (IGF-1) increased — a pharmacodynamic marker confirming target engagement.
6. The effect was reversible. When the peptide was withdrawn, visceral fat tended to return, showing that continued administration was needed to sustain the reduction.
7. Liver fat signals. Later research extended interest to hepatic fat, with studies examining tesamorelin’s effect on liver fat fraction in fatty-liver models.

The mechanism explains why the tesamorelin visceral fat reduction percentage is so selective. The peptide drives a chain of signaling events that preferentially mobilizes visceral fat:

• It binds GHRH receptors on the pituitary, prompting natural growth hormone pulses.
• Growth hormone promotes lipolysis — the breakdown of stored triglycerides.
• Visceral adipose tissue is especially sensitive to growth hormone-driven lipolysis.
• The pulsatile pattern mimics physiological release, unlike steady exogenous growth hormone.
• Elevated IGF-1 reflects downstream activity and serves as a research biomarker.

This upstream approach is the reason tesamorelin reduces visceral fat more selectively than blunt growth hormone administration, while leaving subcutaneous stores comparatively intact.

The original research population — subjects with excess visceral adipose tissue — made tesamorelin a natural model compound for studying central adiposity. Visceral fat is metabolically active and associated with lipid and glucose dysregulation, so a compound that selectively reduces it offers a clean research model. This is why the tesamorelin visceral fat reduction percentage remains a reference figure in metabolic peptide studies.

Tesamorelin’s status as a GHRH analog — rather than direct growth hormone — is central to interpreting its data. By prompting the pituitary to release the body’s own growth hormone in pulses, it preserves physiological feedback loops. The hypothalamic-pituitary axis can still modulate output, which differentiates the research profile from steady exogenous growth hormone.

For researchers, this means IGF-1 elevation serves as a built-in pharmacodynamic readout, and the visceral-fat selectivity becomes easier to explain mechanistically. The peptide’s stabilized structure also extends its functional half-life compared with native GHRH, which degrades rapidly.

Interest has expanded well beyond the original visceral-fat endpoint. Recent investigative directions include:

• Hepatic fat: studies examining liver fat fraction and fatty-liver research models.
• Cognitive research: exploratory work on growth hormone axis signaling and brain aging.
• Cardiometabolic markers: continued analysis of lipid and inflammatory parameters.
• Combination protocols: comparative research alongside other metabolic peptides.

These directions keep tesamorelin relevant in the latest research conversations and reinforce its position as a well-characterized reference compound.

Reconstitution & Concentration in Tesamorelin Research

Accurate concentration is critical when interpreting any VAT research figure. Inconsistent reconstitution introduces variability that can obscure results. Researchers typically:

• Calculate target concentration before adding bacteriostatic water.
• Add diluent slowly down the vial wall to protect the peptide.
• Swirl rather than shake to avoid mechanical degradation.
• Confirm unit math using the péptido de la calculadora.

In documented protocols, tesamorelin is handled as a lyophilized research peptide: reconstituted with bacteriostatic water, stored cold, and logged against a certificate of analysis. Consistent handling is what makes the visceral fat reduction data reproducible across studies. Researchers sourcing reference material should prioritize verified purity and documented COAs over price alone.

Reproducible research depends on reproducible inputs. 99 Purity Peptides supplies reference-grade research compounds with documentation built for laboratory standards:

• Third-party tested purity with published certificates of analysis (COA).
• Lyophilized peptides handled and shipped to preserve stability.
• Exact-milligram labeling for precise concentration math.
• Research-use-only framing with transparent specifications.
• Free dosing and concentration tools, including the reconstitution calculator.

Lyophilized vs Reconstituted Tesamorelin: What the Research Shows

Tesamorelin is supplied lyophilized (freeze-dried) because the peptide is more stable in dry form. Reconstituted solution has a shorter usable window and must be refrigerated. For research storage, the lyophilized form is preferred for long-term reference material, while reconstituted solution is prepared close to the time of use.

Tesamorelin vs Retatrutide: Understanding the Difference

These two compounds are often searched together, but they model different things. Tesamorelin is a GHRH analog studied specifically for visceral fat reduction, with a measured VAT percentage. Retatrutide is a triple-agonist studied for broad body-weight change. A researcher modeling central adiposity selectively would reference tesamorelin; one modeling global weight change would reference retatrutide. They are complementary reference points, not substitutes.

Tesamorelin’s well-documented Phase 3 record makes it a durable reference compound. As research extends into hepatic fat, cardiometabolic markers, and combination protocols, the original visceral fat reduction data remains the anchor figure. Its mechanism — pulsatile, upstream, and selective — continues to make it a model peptide for metabolic study, and the latest 2025–2026 research keeps building on that foundation.

Across Phase 3 trials, the tesamorelin visceral fat reduction percentage lands consistently near 15–18% at 26 weeks, with effects appearing by week 13, selectivity for visceral over subcutaneous fat, and reversibility on discontinuation. Few research peptides offer this level of documented, CT-measured specificity. For laboratories seeking a well-characterized metabolic reference compound, tesamorelin remains one of the most rigorously studied options available — and reproducible results start with verified, reference-grade material.